Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM.

Neuropharmacology. 2019 Mar 30;151:1-12. doi: 10.1016/j.neuropharm.2019.03.033. [Epub ahead of print]

PMID:
30940536
2.

Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.

Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM, Thakur GA.

ACS Chem Neurosci. 2017 Jun 21;8(6):1188-1203. doi: 10.1021/acschemneuro.6b00310. Epub 2017 Feb 7.

PMID:
28103441
3.

Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.

Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M.

Neuroscience. 2009 Sep 29;163(1):456-65. doi: 10.1016/j.neuroscience.2009.06.014. Epub 2009 Jun 10.

PMID:
19524019
4.

Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons.

Mitjavila J, Yin D, Kulkarni PM, Zanato C, Thakur GA, Ross R, Greig I, Mackie K, Straiker A.

Pharmacol Res. 2018 Mar;129:475-481. doi: 10.1016/j.phrs.2017.11.019. Epub 2017 Nov 20.

5.

The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM.

J Ocul Pharmacol Ther. 2017 Oct;33(8):582-590. doi: 10.1089/jop.2017.0037. Epub 2017 Jul 18.

6.

Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG.

Biol Psychiatry. 2018 Nov 15;84(10):722-733. doi: 10.1016/j.biopsych.2017.06.032. Epub 2017 Jul 8.

7.

Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.

Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, Raymond LA.

J Neurosci. 2018 Jan 17;38(3):544-554. doi: 10.1523/JNEUROSCI.1739-17.2017. Epub 2017 Nov 30.

8.

Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM.

Eur J Biochem. 2004 Dec;271(23-24):4909-20.

9.

Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.

Lastres-Becker I, Berrendero F, Lucas JJ, Martín-Aparicio E, Yamamoto A, Ramos JA, Fernández-Ruiz JJ.

Brain Res. 2002 Mar 8;929(2):236-42.

PMID:
11864629
10.

Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.

Dowie MJ, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M.

Neuroscience. 2010 Sep 29;170(1):324-36. doi: 10.1016/j.neuroscience.2010.06.056. Epub 2010 Jul 1.

PMID:
20600638
11.

In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system.

Bari M, Battista N, Valenza M, Mastrangelo N, Malaponti M, Catanzaro G, Centonze D, Finazzi-Agrò A, Cattaneo E, Maccarrone M.

FEBS J. 2013 Jul;280(14):3376-88. doi: 10.1111/febs.12329. Epub 2013 Jun 10.

12.

Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease.

Pietropaolo S, Bellocchio L, Ruiz-Calvo A, Cabanas M, Du Z, Guzmán M, Garret M, Cho YH.

Neuropharmacology. 2015 Feb;89:368-74. doi: 10.1016/j.neuropharm.2014.07.021. Epub 2014 Aug 11.

PMID:
25123645
13.

Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.

Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V.

Neurochem Int. 2008 Jan;52(1-2):307-13. Epub 2007 Jul 4.

PMID:
17664017
14.

Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.

Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM.

Methods Mol Biol. 2018;1780:549-571. doi: 10.1007/978-1-4939-7825-0_25.

PMID:
29856035
15.

The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.

Laprairie RB, Warford JR, Hutchings S, Robertson GS, Kelly ME, Denovan-Wright EM.

J Neuroimmunol. 2014 Feb 15;267(1-2):61-72. doi: 10.1016/j.jneuroim.2013.12.008. Epub 2013 Dec 12.

PMID:
24360910
16.

Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.

Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M, Calabresi P.

Biol Psychiatry. 2005 Jun 15;57(12):1583-9.

PMID:
15953496
17.

Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.

Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RL.

Neuroscience. 2004;123(1):207-12.

PMID:
14667455
18.

Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.

Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernandez-Ruiz J, Bormans G, Van Laere K, Casteels C.

Neurobiol Aging. 2014 Dec;35(12):2858-2869. doi: 10.1016/j.neurobiolaging.2014.06.010. Epub 2014 Jun 16.

PMID:
25018107
19.

Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.

Dufour BD, McBride JL.

Neurobiol Dis. 2019 Jan;121:214-229. doi: 10.1016/j.nbd.2018.09.025. Epub 2018 Oct 5.

20.

Supplemental Content

Support Center